Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Novo Nordisk Opens Second R&D Center in Beijing

publication date: Sep 24, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Novo Nordisk, the Danish drug company known for its diabetes focus, officially opened a new $100 million R&D center in Beijing’s Zhongguancun Life Science Park, near the company’s existing facility. The new center will allow the company to increase R&D staffing in China from 130 to 200 in the immediate future. With the increased capacity, the center is now able to conduct the full range of protein research in China, according to Novo Nordisk. More details....

Stock Symbol: (NYSE: NVO)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...